Breaking News Instant updates and real-time market news.

AL

Air Lease

$43.19 /

-1.3 (-2.92%)

, EADSY

Airbus

$28.90 /

-0.96 (-3.22%)

06:34
12/14/21
12/14
06:34
12/14/21
06:34

Air Lease announces lease placement of two new Airbus A350-1000 aircraft

Air Lease (AL) announced long-term lease placements for two new Airbus (EADSY) A350-1000 aircraft with Virgin Atlantic. The two new A350-1000s are scheduled to deliver to the airline in 2023 and 2024 from ALC's orderbook with Airbus.

AL

Air Lease

$43.19 /

-1.3 (-2.92%)

EADSY

Airbus

$28.90 /

-0.96 (-3.22%)

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
R1 RCM to host conference call » 01:03
06/26/22
06/26
01:03
06/26/22
01:03
RCM

R1 RCM

$21.67 /

+0.63 (+2.99%)

Conference call to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RCM R1 RCM
$21.67 /

+0.63 (+2.99%)

RCM R1 RCM
$21.67 /

+0.63 (+2.99%)

05/10/22 Deutsche Bank
R1 RCM price target lowered to $28 from $30 at Deutsche Bank
04/13/22 Guggenheim
R1 RCM initiated with a Neutral at Guggenheim
03/03/22 Baird
R1 RCM price target raised to $32 from $29 at Baird
02/09/22 Deutsche Bank
R1 RCM initiated with a Buy at Deutsche Bank
RCM R1 RCM
$21.67 /

+0.63 (+2.99%)

Conference/Events
Thor Industries to host investor day » 00:36
06/26/22
06/26
00:36
06/26/22
00:36
THO

Thor Industries

$79.39 /

+2.83 (+3.70%)

Investor Day to be held…

Investor Day to be held in Jackson Center, Ohio on June 27 at 9 am. Webcast Link

ShowHide Related Items >><<
THO Thor Industries
$79.39 /

+2.83 (+3.70%)

THO Thor Industries
$79.39 /

+2.83 (+3.70%)

06/09/22 Baird
Thor Industries price target lowered to $100 from $120 at Baird
05/19/22 DA Davidson
Thor Industries cut to Underperform at DA Davidson amid retail weakness
05/19/22 DA Davidson
Thor Industries downgraded to Underperform from Neutral at DA Davidson
05/16/22 BMO Capital
Thor Industries price target lowered to $95 from $110 at BMO Capital
THO Thor Industries
$79.39 /

+2.83 (+3.70%)

THO Thor Industries
$79.39 /

+2.83 (+3.70%)

Conference/Events
One Stop Systems participates in a conference call with Benchmark » 00:31
06/26/22
06/26
00:31
06/26/22
00:31
OSS

One Stop Systems

$3.96 /

-0.02 (-0.50%)

Semiconductor Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

08/16/21 Benchmark
One Stop Systems assumed with a Buy at Benchmark
07/07/21
Fly Intel: Top five analyst initiations
07/07/21 Lake Street
One Stop Systems initiated with a Buy at Lake Street
OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

OSS One Stop Systems
$3.96 /

-0.02 (-0.50%)

Conference/Events
Relay Therapeutics to hold virtual event » 16:58
06/25/22
06/25
16:58
06/25/22
16:58
RLAY

Relay Therapeutics

$20.87 /

+1.87 (+9.84%)

Virtual Investor and…

Virtual Investor and Analyst Event to be held on June 27 at 8 am. Webcast Link

ShowHide Related Items >><<
RLAY Relay Therapeutics
$20.87 /

+1.87 (+9.84%)

RLAY Relay Therapeutics
$20.87 /

+1.87 (+9.84%)

06/06/22 Jefferies
Relay Therapeutics initiated with an Underperform at Jefferies
05/10/22 H.C. Wainwright
Relay Therapeutics price target lowered to $47 from $54 at H.C. Wainwright
05/09/22 JMP Securities
Relay Therapeutics price target lowered to $35 from $50 at JMP Securities
02/01/22 Berenberg
Relay Therapeutics initiated with a Buy at Berenberg
RLAY Relay Therapeutics
$20.87 /

+1.87 (+9.84%)

  • 13
    Oct
Conference/Events
Qurate Retail to hold a virtual investor event » 16:54
06/25/22
06/25
16:54
06/25/22
16:54
QRTEA

Qurate Retail

$3.43 /

+0.015 (+0.44%)

CEO Rawlinson holds a…

CEO Rawlinson holds a Virtual Investor Event to be held on June 27 at 9:30 am. Webcast Link

ShowHide Related Items >><<
QRTEA Qurate Retail
$3.43 /

+0.015 (+0.44%)

QRTEA Qurate Retail
$3.43 /

+0.015 (+0.44%)

02/28/22 BofA
Qurate Retail cut to Neutral at BofA amid competitive and execution issues
02/28/22 BofA
Qurate Retail downgraded to Neutral from Buy at BofA
QRTEA Qurate Retail
$3.43 /

+0.015 (+0.44%)

Recommendations
Accenture price target lowered to $370 from $455 at Barclays » 12:41
06/25/22
06/25
12:41
06/25/22
12:41
ACN

Accenture

$299.36 /

+13.3 (+4.65%)

Barclays analyst Ramsey…

Barclays analyst Ramsey El-Assal lowered the firm's price target on Accenture to $370 from $455 and keeps an Overweight rating on the shares following the fiscal Q3 results. The analyst reduced Accenture's valuation multiple saying market multiples for companies in the IT Services sector have compressed materially.

ShowHide Related Items >><<
ACN Accenture
$299.36 /

+13.3 (+4.65%)

ACN Accenture
$299.36 /

+13.3 (+4.65%)

06/24/22 RBC Capital
Accenture price target lowered to $357 from $435 at RBC Capital
06/24/22 Cowen
Accenture price target lowered to $325 from $330 at Cowen
06/24/22 Baird
Accenture price target lowered to $310 from $340 at Baird
06/24/22 Morgan Stanley
Accenture price target lowered to $385 from $390 at Morgan Stanley
ACN Accenture
$299.36 /

+13.3 (+4.65%)

ACN Accenture
$299.36 /

+13.3 (+4.65%)

ACN Accenture
$299.36 /

+13.3 (+4.65%)

Recommendations
Zendesk price target lowered to $77.50 from $128 at UBS » 11:02
06/25/22
06/25
11:02
06/25/22
11:02
ZEN

Zendesk

$74.05 /

+16.03 (+27.63%)

UBS analyst Taylor…

UBS analyst Taylor McGinnis lowered the firm's price target on Zendesk to $77.50 from $128 and keeps a Neutral rating on the shares. The analyst cited the company's announcement that it entered into a definitive agreement to be acquired for $77.50/share.

ShowHide Related Items >><<
ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

06/24/22 Stifel
Stifel keeps Buy rating on Zendesk, doesn't see 'end of the road quite yet'
06/24/22 Canaccord
Zendesk downgraded to Hold from Buy at Canaccord
06/24/22 Jefferies
Competing Zendesk bid 'possible, but not probable,' says Jefferies
06/24/22 Piper Sandler
Zendesk deal premium 'appears underwhelming,' says Piper Sandler
ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

ZEN Zendesk
$74.05 /

+16.03 (+27.63%)

Recommendations
Walgreens Boots Alliance price target lowered to $45 from $50 at Barclays » 10:58
06/25/22
06/25
10:58
06/25/22
10:58
WBA

Walgreens Boots Alliance

$41.66 /

+0.77 (+1.88%)

Barclays analyst Steve…

Barclays analyst Steve Valiquette lowered the firm's price target on Walgreens Boots Alliance to $45 from $50 and keeps an Equal Weight rating on the shares. With a number of perceived overhangs on the retail segment going into the remainder of the year, focus for Walgreens' Q3 print will be on the outlook for foot traffic and front-end inventory/supply chain risk, the analyst said in a research note on Friday. For Q3 itself, Valiquette projects EPS of 88c versus Street view of 93c.

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

04/12/22 Cowen
Walgreens Boots Alliance price target lowered to $50 from $55 at Cowen
04/05/22 Deutsche Bank
Walgreens price target lowered to $46 from $52 at Deutsche Bank
04/05/22 UBS
Walgreens Boots Alliance price target lowered to $49 from $52 at UBS
04/01/22 Truist
Walgreens Boots Alliance price target lowered to $50 from $58 at Truist
WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

WBA Walgreens Boots Alliance
$41.66 /

+0.77 (+1.88%)

Hot Stocks
Pfizer, BioNTech announce data evaluating omicron-adapted vaccine candidates » 10:54
06/25/22
06/25
10:54
06/25/22
10:54
PFE

Pfizer

$51.60 /

+1.51 (+3.01%)

, BNTX

BioNTech

$133.98 /

+1.73 (+1.31%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech (BNTX) announced positive data evaluating the safety, tolerability, and immunogenicity of two omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies' current COVID-19 vaccine. The robust immune response was seen across two investigational dose levels, 30 microgram and 60 microgram. The Omicron adapted vaccine candidates studied in the Phase 2/3 trial in 1,234 participants 56 years of age and older elicited substantially higher neutralizing antibody responses against Omicron BA.1 when compared to the companies' current COVID-19 vaccine. The pre-specified criterion for superiority was measured by the ratio of neutralizing geometric mean titers with the lower bound of the 95% confidence interval greater than 1. The geometric mean ratios for the monovalent 30 microgram and 60 microgram vaccines compared to the current COVID-19 vaccine were 2.23 and 3.15, respectively. The GMRs for the bivalent 30 microgram and 60 microgram vaccines compared to the current COVID-19 vaccine were 1.56 and 1.97, respectively. The monovalent Omicron-adapted vaccine 30 microgram and 60 microgram achieved a lower bound 95% confidence interval for GMR of greater than1.5, consistent with the regulatory requirement of super superiority. Demonstration of superiority against omicron and safety are regulatory requirements for potential emergency use authorization of a variant-adapted vaccine. One month after administration, a booster dose of the omicron-adapted monovalent candidates increased neutralizing geometric mean titers against Omicron BA.1 13.5 and 19.6-fold above pre-booster dose levels, while a booster dose of the Omicron-adapted bivalent candidates conferred a 9.1 and 10.9-fold increase in neutralizing GMTs against Omicron BA.1. Both omicron-adapted vaccine candidates were well-tolerated in participants who received one or the other omicron-adapted vaccine. In a SARS-CoV-2 live virus neutralization assay tested on sera from participants over 56 years of age and older, sera efficiently neutralized BA.4/BA.5 with titers approximately 3-fold lower than BA.1. Pfizer and BioNTech will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.

ShowHide Related Items >><<
PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
06/03/22 Oppenheimer
Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
05/31/22 Evercore ISI
Enanta upgraded to In Line from Underperform at Evercore ISI
BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

PFE Pfizer
$51.60 /

+1.51 (+3.01%)

BNTX BioNTech
$133.98 /

+1.73 (+1.31%)

Hot Stocks
Ionis announces presentation of Phase 2b data for chronic hepatitis B treatment » 10:49
06/25/22
06/25
10:49
06/25/22
10:49
IONS

Ionis Pharmaceuticals

$39.17 /

+0.14 (+0.36%)

, GSK

GSK plc

$43.69 /

+0.93 (+2.17%)

Ionis Pharmaceuticals…

Ionis Pharmaceuticals announced that GSK (GSK) presented results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen - formerly IONIS-HBVRx, an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus. The data were presented in an oral late-breaker session at the European Association for the Study of the Liver's International Liver Congress 2022 in London, U.K. The final results from the study will be submitted for presentation at a scientific congress later this year, and for publication in a peer-reviewed journal. In the study, 28% of patients on standard of care, which is stable nucleoside/nucleotide analogue, and 29% of patients not on NA treatment, experienced a virologic response on 300 mg of bepirovirsen weekly, following 24 weeks of treatment. Virologic response is defined as serum/plasma levels of hepatitis B virus DNA and hepatitis B surface antigens below the lower limit of quantification. Up to 68% of patients on NA therapy and up to 65% of patients not on NA achieved HBsAg less than100 IU/mL at the end of treatment. End-of-treatment virologic responses were observed in patients with high or low baseline HBsAg levels, who were hepatitis B e-antigen negative or positive, and who were receiving NA treatment or not, indicating that bepirovirsen has the potential to treat broad segments of the CHB population. Durability of the responses is being assessed. Treatment-related serious adverse events were observed in less than 1% of patients receiving NA treatment and 1% of patients who were not on NA. SAEs were reported in 3% and 4% of patients receiving NA treatment and those who were not on NA, respectively. There were no clinically meaningful differences in adverse events across treatment arms in either trial. GSK is also exploring combinations of bepirovirsen and other therapeutic modalities in the following trials. Combination treatments could increase functional cure rates in more patients, thereby further reducing the global disease burden of CHB. Trials include:

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

06/23/22 Citi
Citi adds AutoZone, Thermo Fisher, Ionis to 'Focus List'
06/21/22 Piper Sandler
Ionis told Piper eplontersen efficacy competitive with Amvuttra
06/10/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $55 from $54 at Piper Sandler
05/05/22 Stifel
Ionis Pharmaceuticals price target raised to $33 from $31 at Stifel
GSK GSK plc
$43.69 /

+0.93 (+2.17%)

05/19/22 Deutsche Bank
GlaxoSmithKline price target raised to 1,750 GBp at Deutsche Bank
05/17/22 Roth Capital
Ideaya Biosciences price target raised to $46 from $42 at Roth Capital
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
04/29/22 Barclays
GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays
IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

IONS Ionis Pharmaceuticals
$39.17 /

+0.14 (+0.36%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

GSK GSK plc
$43.69 /

+0.93 (+2.17%)

Periodicals
GM stock looking like a bargain after begin hammered, Barron's says » 10:41
06/25/22
06/25
10:41
06/25/22
10:41
GM

General Motors

$34.83 /

+1.845 (+5.59%)

Inflation, rising…

Inflation, rising interest rates, and recession fears have all conspired against General Motors stock. Its shares are still worth owning, Al Root writes in this week's edition of Barron's. The good news for value investors is that the auto sector is now pricing in a recession-full stop, the author says. GM stock, at about five times 2023 earnings estimates, is cheaper now than it was through the depths of the pandemic. Based on that alone, it would be a terrible time to abandon ship now, Root adds. Reference Link

ShowHide Related Items >><<
GM General Motors
$34.83 /

+1.845 (+5.59%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

06/16/22 Goldman Sachs
Goldman left Samsara analyst day with stronger conviction
06/07/22 Morgan Stanley
MP Materials price target raised to $46 from $42 at Morgan Stanley
06/01/22 Goldman Sachs
General Motors price target lowered to $46 from $59 at Goldman Sachs
06/01/22 Citi
General Motors price target lowered to $87 from $98 at Citi
GM General Motors
$34.83 /

+1.845 (+5.59%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

GM General Motors
$34.83 /

+1.845 (+5.59%)

Periodicals
Lucid stock looks more vulnerable than Tesla, other peers, Barron's says » 10:35
06/25/22
06/25
10:35
06/25/22
10:35
LCID

Lucid Group

$19.21 /

-0.09 (-0.47%)

, TSLA

Tesla

$737.59 /

+31.915 (+4.52%)

, PSNY

Polestar

$12.82 /

-0.08 (-0.62%)

, XPEV

XPeng

$35.32 /

+2.31 (+7.00%)

, NIO

Nio

$24.08 /

+1 (+4.33%)

, LI

Li Auto

$40.79 /

+1.56 (+3.98%)

, RIVN

Rivian Automotive

$29.52 /

+0.06 (+0.20%)

The issue with Lucid…

The issue with Lucid (LCID) is not direct competition; the issue is valuation, Al Root writes in this week's edition of Barron's. Lucid, with a value of about $29 billion, is priced at more than eight times 2023 sales of $3.5 billion. That's not just expensive relative to Polestar (PSNY) but also to XPeng (XPEV), NIO (NIO), Li Auto (LI), and Rivian Automotive (RIVN) - all EV companies with sales, but no free cash flow yet, that trade for around 2.6 times 2023 sales. The fundamental risk for Lucid-which sold roughly 500 cars in the past two quarters and is expected to sell about 13,000 in 2022-is that volumes will flatten out or decline as the upper end of the EV market gets saturated. That would be very bad news for Lucid's multiple, the author contends. Reference Link

ShowHide Related Items >><<
XPEV XPeng
$35.32 /

+2.31 (+7.00%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

PSNY Polestar
$12.82 /

-0.08 (-0.62%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

06/06/22 Deutsche Bank
Tesla workforce reduction 'direct warning' to industry, says Deutsche Bank
05/09/22 Citi
Lucid Group price target lowered to $36 from $45 at Citi
05/06/22 Morgan Stanley
Lucid production view looks more bull case than base case, says Morgan Stanley
04/25/22 Wells Fargo
Wells says Wolfspeed design win with Lucid further validation of SiC portfolio
TSLA Tesla
$737.59 /

+31.915 (+4.52%)

06/24/22 Credit Suisse
Credit Suisse cuts Tesla cut, sees Q2 deliveries below consensus
06/22/22 Morgan Stanley
Tesla price target lowered to $1,200 from $1,300 at Morgan Stanley
06/15/22 Mizuho
Mizuho likes three electric vehicle stocks into second half rebound
06/14/22 Morgan Stanley
Morgan Stanley says 'very prudent' to shift some Tesla production to Q3 from Q2
PSNY Polestar
$12.82 /

-0.08 (-0.62%)

XPEV XPeng
$35.32 /

+2.31 (+7.00%)

06/21/22 Citi
XPeng price target raised to $51.59 from $36.70 at Citi
05/24/22 JPMorgan
XPeng price target lowered to $35 from $42 at JPMorgan
05/24/22 Barclays
XPeng price target lowered to $30 from $39 at Barclays
05/24/22 BofA
XPeng price target lowered to $40 from $46 at BofA
NIO Nio
$24.08 /

+1 (+4.33%)

06/21/22 Citi
Nio price target lowered to $41.10 from $87 at Citi
06/17/22 Morgan Stanley
Nio's recent outperformance has several drivers, says Morgan Stanley
06/15/22 Morgan Stanley
Nio's ES7, SUV upgrades should meet expectations, says Morgan Stanley
LI Li Auto
$40.79 /

+1.56 (+3.98%)

06/21/22 Citi
Li Auto price target raised to $58.60 from $26.80 at Citi
05/11/22 Citi
Li Auto price target lowered to $26.80 from $51.50 at Citi
05/10/22 BofA
Li Auto price target lowered to $33 from $35 at BofA
04/04/22 UBS
Li Auto price target raised to $52 from $47 at UBS
RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

06/01/22 DA Davidson
DA Davidson starts Rivian Automotive with sell on headline worries
06/01/22 DA Davidson
Rivian Automotive initiated with an Underperform at DA Davidson
XPEV XPeng
$35.32 /

+2.31 (+7.00%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

  • 10
    Nov
  • 13
    Aug
XPEV XPeng
$35.32 /

+2.31 (+7.00%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

NIO Nio
$24.08 /

+1 (+4.33%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

XPEV XPeng
$35.32 /

+2.31 (+7.00%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

XPEV XPeng
$35.32 /

+2.31 (+7.00%)

TSLA Tesla
$737.59 /

+31.915 (+4.52%)

RIVN Rivian Automotive
$29.52 /

+0.06 (+0.20%)

PSNY Polestar
$12.82 /

-0.08 (-0.62%)

NIO Nio
$24.08 /

+1 (+4.33%)

LI Li Auto
$40.79 /

+1.56 (+3.98%)

LCID Lucid Group
$19.21 /

-0.09 (-0.47%)

Periodicals
Kellogg's move to split into 3 companies not as flaky as it looks, Barron's says » 10:30
06/25/22
06/25
10:30
06/25/22
10:30
K

Kellogg

$70.73 /

+1.44 (+2.08%)

Kellogg surprised…

Kellogg surprised investors this past week by announcing plans to split into three pieces. That's a little puzzling, but the stock might still be worth a look, Teresa Rivas writes in this week's edition of Barron's. The three businesses it plans to create, focused on the cereal business, global snacking, and plant-based protein products, aren't all that different from each other, and it's unclear whether they will be worth more apart than they are together. Still, the shares look attractive for investors in search of a food stock in a tough market, the author argues. Reference Link

ShowHide Related Items >><<
K Kellogg
$70.73 /

+1.44 (+2.08%)

K Kellogg
$70.73 /

+1.44 (+2.08%)

06/22/22 JPMorgan
Kellogg breakup likely doesn't alter share valuation, says JPMorgan
06/22/22 Deutsche Bank
Kellogg price target lowered to $72 from $74 at Deutsche Bank
06/22/22 Citi
Kellogg price target raised to $87 from $83 at Citi
06/21/22 Stifel
Stifel views Kellogg breakup announcement as positive for stock
K Kellogg
$70.73 /

+1.44 (+2.08%)

K Kellogg
$70.73 /

+1.44 (+2.08%)

K Kellogg
$70.73 /

+1.44 (+2.08%)

K Kellogg
$70.73 /

+1.44 (+2.08%)

Periodicals
Investors should buy Starbucks as worst problems now behind it, Barron's says » 10:26
06/25/22
06/25
10:26
06/25/22
10:26
SBUX

Starbucks

$78.10 /

+2.9 (+3.86%)

While same-store sales in…

While same-store sales in China fell 23% year over year during the second quarter, the country has lifted some of its COVID-related restrictions in May and Starbucks' should start to improve and might even return to pre-COVID levels by the first half of 2023, Jacob Sonenshine writes in this week's edition of Barron's. Starbucks should also continue to see a recovery in the U.S. But growing sales won't help much if Starbucks can't turn more of its revenue into profits, the author notes. If Starbucks can hit those numbers, the stock could be, if not a bargain, at least quite compelling at current valuations, the publication adds. Reference Link

ShowHide Related Items >><<
SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

05/09/22 Deutsche Bank
Starbucks price target lowered to $103 from $116 at Deutsche Bank
05/04/22 MKM Partners
Starbucks price target lowered to $98 from $105 at MKM Partners
05/04/22 Morgan Stanley
Starbucks price target lowered to $87 from $94 at Morgan Stanley
05/04/22 Cowen
Starbucks price target lowered to $94 from $115 at Cowen
SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

SBUX Starbucks
$78.10 /

+2.9 (+3.86%)

On The Fly
Opening Day: Golden Sun rises in debut as Ivanhoe Electric delays IPO » 10:19
06/25/22
06/25
10:19
06/25/22
10:19
GSUN

Golden Sun Education Group

$19.88 /

-1.125 (-5.36%)

, SVRE

SaverOne 2014

$2.53 /

+0.04 (+1.61%)

, TOP

Zhong Yang Financial

$35.18 /

-6.14 (-14.86%)

, IE

Ivanhoe Electric

/

+

, STWY

Steinway

/

+

, GS

Goldman Sachs

$303.08 /

+16.73 (+5.84%)

, JPM

JPMorgan

$117.36 /

+3.415 (+3.00%)

, AMZN

Amazon.com

$116.68 /

+4.15 (+3.69%)

, UBER

Uber

$23.06 /

+0.685 (+3.06%)

, DASH

DoorDash

$74.15 /

+3.84 (+5.46%)

, BHC

Bausch Health

$8.76 /

+1.475 (+20.26%)

, PYPL

PayPal

$77.65 /

+3.83 (+5.19%)

, SQ

Block

$71.01 /

+3.7 (+5.50%)

, AFRM

Affirm

$23.31 /

+1.64 (+7.57%)

, ZIZTF

Zip Co.

/

+

, GDST

Goldenstone Acquisition

$9.90 /

-0.005 (-0.05%)

Chinese tutorial services…

ShowHide Related Items >><<
UBER Uber
$23.06 /

+0.685 (+3.06%)

TOP Zhong Yang Financial
$35.18 /

-6.14 (-14.86%)

SQ Block
$71.01 /

+3.7 (+5.50%)

PYPL PayPal
$77.65 /

+3.83 (+5.19%)

JPM JPMorgan
$117.36 /

+3.415 (+3.00%)

GSUN Golden Sun Education Group
$19.88 /

-1.125 (-5.36%)

GS Goldman Sachs
$303.08 /

+16.73 (+5.84%)

GDST Goldenstone Acquisition
$9.90 /

-0.005 (-0.05%)

DASH DoorDash
$74.15 /

+3.84 (+5.46%)

BHC Bausch Health
$8.76 /

+1.475 (+20.26%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

AFRM Affirm
$23.31 /

+1.64 (+7.57%)

GSUN Golden Sun Education Group
$19.88 /

-1.125 (-5.36%)

SVRE SaverOne 2014
$2.53 /

+0.04 (+1.61%)

TOP Zhong Yang Financial
$35.18 /

-6.14 (-14.86%)

IE Ivanhoe Electric
/

+

STWY Steinway
/

+

GS Goldman Sachs
$303.08 /

+16.73 (+5.84%)

05/03/22 Oppenheimer
Goldman Sachs price target lowered to $519 from $546 at Oppenheimer
04/18/22 Gordon Haskett
Block director exit notable due to 'overlap' language, says Gordon Haskett
04/18/22 BMO Capital
Goldman Sachs price target lowered to $486 from $488 at BMO Capital
04/05/22 Piper Sandler
Goldman Sachs price target lowered to $430 from $465 at Piper Sandler
JPM JPMorgan
$117.36 /

+3.415 (+3.00%)

06/24/22 Morgan Stanley
JPMorgan price target lowered to $149 from $152 at Morgan Stanley
05/24/22 Societe Generale
Societe Generale upgrades JPMorgan with $150 target after investor day
05/24/22 Societe Generale
JPMorgan upgraded to Buy from Hold at Societe Generale
05/24/22 BMO Capital
JPMorgan price target raised to $156 from $150 at BMO Capital
AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

06/24/22 Evercore ISI
Amazon price target lowered to $180 from $205 at Evercore ISI
06/16/22 Credit Suisse
Credit Suisse says Microsoft Azure growth opportunity not reflected in estimates
06/14/22 Morgan Stanley
AWS has 'small' risk from potential start-up spend slowdown, says Morgan Stanley
06/14/22 JPMorgan
Amazon remains best idea at JPMorgan with $200 price target
UBER Uber
$23.06 /

+0.685 (+3.06%)

06/24/22 Wolfe Research
Uber price target lowered to $27 from $30 at Wolfe Research
06/16/22 Mizuho
Uber hits 'speed bump' in Massachusetts, says Mizuho
06/09/22 Goldman Sachs
Uber price target lowered to $45 from $55 at Goldman Sachs
06/08/22 Barclays
Barclays ups Uber target, says time to revisit long thesis
DASH DoorDash
$74.15 /

+3.84 (+5.46%)

06/21/22 Goldman Sachs
DoorDash reinstated with a Neutral at Goldman Sachs
06/06/22 Raymond James
DoorDash initiated with a Market Perform at Raymond James
06/03/22 DA Davidson
DoorDash price target lowered to $82 from $135 at DA Davidson
06/02/22 JMP Securities
DoorDash price target lowered to $150 from $200 at JMP Securities
BHC Bausch Health
$8.76 /

+1.475 (+20.26%)

06/13/22 JPMorgan
Bausch Health resumed with an Overweight at JPMorgan
05/31/22 BofA
Bausch + Lomb initiated with a Buy at BofA
05/26/22 Piper Sandler
Bausch Health price target lowered to $7 from $27 at Piper Sandler
05/11/22 BMO Capital
Bausch Health price target lowered to $15 from $26 at BMO Capital
PYPL PayPal
$77.65 /

+3.83 (+5.19%)

06/22/22 Credit Suisse
PayPal price target lowered to $95 from $100 at Credit Suisse
06/07/22 Mizuho
PayPal sales could rise 20% if Apple enables Venmo tap, says Mizuho
06/06/22 Wedbush
Wedbush says bottoming ecommerce trends should address visibility at PayPal
06/01/22 Piper Sandler
App downloads for Block's Cash App strong, says Piper Sandler
SQ Block
$71.01 /

+3.7 (+5.50%)

06/17/22 Mizuho
Marqeta has negotiating leverage with Square, says Mizuho
06/15/22 Credit Suisse
Block price target lowered to $170 from $180 at Credit Suisse
AFRM Affirm
$23.31 /

+1.64 (+7.57%)

06/22/22 Mizuho
Affirm credit trends 'look slightly less optimistic,' says Mizuho
06/07/22 Wedbush
Wedbush starts Affirm at Underperform with $15 price target
06/07/22 Wedbush
Affirm initiated with an Underperform at Wedbush
06/07/22 Morgan Stanley
Apple BNPL entry likely doesn't change landscape for Affirm, says Morgan Stanley
ZIZTF Zip Co.
/

+

02/28/22 Jefferies
Zip Co. downgraded to Underperform from Hold at Jefferies
10/13/21 Citi
Zip Co. downgraded to Neutral from Buy at Citi
09/30/21 Jefferies
Zip Co. downgraded to Hold from Buy at Jefferies
GDST Goldenstone Acquisition
$9.90 /

-0.005 (-0.05%)

UBER Uber
$23.06 /

+0.685 (+3.06%)

SQ Block
$71.01 /

+3.7 (+5.50%)

PYPL PayPal
$77.65 /

+3.83 (+5.19%)

JPM JPMorgan
$117.36 /

+3.415 (+3.00%)

GS Goldman Sachs
$303.08 /

+16.73 (+5.84%)

DASH DoorDash
$74.15 /

+3.84 (+5.46%)

BHC Bausch Health
$8.76 /

+1.475 (+20.26%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

AFRM Affirm
$23.31 /

+1.64 (+7.57%)

  • 22
    Jun
  • 28
    Jun
  • 01
    Jun
  • 19
    Aug
  • 29
    Jul
UBER Uber
$23.06 /

+0.685 (+3.06%)

SQ Block
$71.01 /

+3.7 (+5.50%)

PYPL PayPal
$77.65 /

+3.83 (+5.19%)

JPM JPMorgan
$117.36 /

+3.415 (+3.00%)

GS Goldman Sachs
$303.08 /

+16.73 (+5.84%)

GDST Goldenstone Acquisition
$9.90 /

-0.005 (-0.05%)

DASH DoorDash
$74.15 /

+3.84 (+5.46%)

BHC Bausch Health
$8.76 /

+1.475 (+20.26%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

UBER Uber
$23.06 /

+0.685 (+3.06%)

SVRE SaverOne 2014
$2.53 /

+0.04 (+1.61%)

STWY Steinway
/

+

SQ Block
$71.01 /

+3.7 (+5.50%)

PYPL PayPal
$77.65 /

+3.83 (+5.19%)

JPM JPMorgan
$117.36 /

+3.415 (+3.00%)

GS Goldman Sachs
$303.08 /

+16.73 (+5.84%)

GDST Goldenstone Acquisition
$9.90 /

-0.005 (-0.05%)

DASH DoorDash
$74.15 /

+3.84 (+5.46%)

BHC Bausch Health
$8.76 /

+1.475 (+20.26%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

AFRM Affirm
$23.31 /

+1.64 (+7.57%)

UBER Uber
$23.06 /

+0.685 (+3.06%)

SQ Block
$71.01 /

+3.7 (+5.50%)

PYPL PayPal
$77.65 /

+3.83 (+5.19%)

JPM JPMorgan
$117.36 /

+3.415 (+3.00%)

GS Goldman Sachs
$303.08 /

+16.73 (+5.84%)

DASH DoorDash
$74.15 /

+3.84 (+5.46%)

BHC Bausch Health
$8.76 /

+1.475 (+20.26%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

AFRM Affirm
$23.31 /

+1.64 (+7.57%)

Periodicals
Cadre to capitalize on renewed emphasis on funding the police, Barron's says » 10:02
06/25/22
06/25
10:02
06/25/22
10:02
CDRE

Cadre

$19.25 /

+0.51 (+2.72%)

Cadre Holdings is a…

Cadre Holdings is a growing company primed to capitalize on a renewed emphasis on funding the police, Nicholas Jasinski writes in this week's edition of Barron's. The company manufactures and sells a range of equipment to police departments and other public safety agencies. In addition to bulletproof vests, that includes handcuffs, holsters, radios, and body armor and specialized gear for SWAT teams and bomb squads. After all the debates over crime and policing in the U.S. over the past two years, funding police is suddenly back in vogue, the author notes. Reference Link

ShowHide Related Items >><<
CDRE Cadre
$19.25 /

+0.51 (+2.72%)

CDRE Cadre
$19.25 /

+0.51 (+2.72%)

06/13/22 B. Riley
Cadre price target raised to $31 from $27 at B. Riley
11/29/21 Lake Street
Cadre initiated with a Buy at Lake Street
11/29/21 B. Riley
Cadre initiated with a Buy, $26 target at B. Riley
11/29/21 Stifel
Cadre initiated with a Hold at Stifel
CDRE Cadre
$19.25 /

+0.51 (+2.72%)

  • 10
    Jun
  • 04
    Nov
CDRE Cadre
$19.25 /

+0.51 (+2.72%)

CDRE Cadre
$19.25 /

+0.51 (+2.72%)

On The Fly
Short Report: Bears undeterred by bounce in growth names » 09:54
06/25/22
06/25
09:54
06/25/22
09:54
CVNA

Carvana

$31.51 /

+2.73 (+9.49%)

, CHWY

Chewy

$38.24 /

+1.59 (+4.34%)

, EVGO

EVgo

$7.65 /

-0.45 (-5.56%)

, LMND

Lemonade

$19.95 /

+0.16 (+0.81%)

, GOEV

Canoo

$2.23 /

-0.025 (-1.11%)

, CTRN

Citi Trends

$25.14 /

+1.16 (+4.84%)

Welcome to this week’s…

ShowHide Related Items >><<
LMND Lemonade
$19.95 /

+0.16 (+0.81%)

GOEV Canoo
$2.23 /

-0.025 (-1.11%)

EVGO EVgo
$7.65 /

-0.45 (-5.56%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CTRN Citi Trends
$25.14 /

+1.16 (+4.84%)

CHWY Chewy
$38.24 /

+1.59 (+4.34%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

06/13/22 Stephens
Carvana price target lowered to $38 from $100 at Stephens
05/19/22 BofA
Carvana price target lowered to $80 from $225 at BofA
05/16/22 Needham
Carvana price target lowered to $80 from $121 at Needham
05/16/22 DA Davidson
Carvana price target lowered to $49 from $140 at DA Davidson
CHWY Chewy
$38.24 /

+1.59 (+4.34%)

06/21/22 Wedbush
Wedbush upgrades Chewy to Outperform on favorable risk/reward
06/21/22 Wedbush
Chewy upgraded to Outperform from Neutral at Wedbush
06/03/22 Wells Fargo
Chewy price target lowered to $55 from $65 at Wells Fargo
06/02/22 Citi
Chewy price target lowered to $29 from $45 at Citi
EVGO EVgo
$7.65 /

-0.45 (-5.56%)

06/08/22 Capital One
EVgo upgraded to Overweight from Equalweight at Capital One
05/16/22 Citi
EVgo price target lowered to $10 from $11 at Citi
05/12/22 Credit Suisse
Credit Suisse upgrades EVgo to Outperform with $14 price target
05/12/22 Credit Suisse
EVgo upgraded to Outperform from Neutral at Credit Suisse
LMND Lemonade
$19.95 /

+0.16 (+0.81%)

05/11/22 Oppenheimer
Lemonade price target lowered to $30 from $45 at Oppenheimer
05/11/22 JMP Securities
Lemonade price target lowered to $40 from $95 at JMP Securities
02/25/22 Barclays
Lemonade price target lowered to $22 from $43 at Barclays
02/25/22 Oppenheimer
Lemonade price target lowered to $45 from $85 at Oppenheimer
GOEV Canoo
$2.23 /

-0.025 (-1.11%)

12/16/21 R.F. Lafferty
Canoo price target raised to $21 from $19 at R.F. Lafferty
12/16/21 Roth Capital
Roth Capital upgrades Canoo to Buy, raises price target to $14
12/16/21 Roth Capital
Canoo upgraded to Buy from Neutral at Roth Capital
12/16/21 R.F. Lafferty
Canoo price target raised to $21 from $19 at R.F. Lafferty
CTRN Citi Trends
$25.14 /

+1.16 (+4.84%)

05/20/22 Craig-Hallum
Citi Trends downgraded to Hold from Buy at Craig-Hallum
05/20/22 Craig-Hallum
Citi Trends downgraded to Hold from Buy at Craig-Hallum
03/16/22 Craig-Hallum
Citi Trends price target lowered to $80 from $100 at Craig-Hallum
02/10/22 Gordon Haskett
Gordon Haskett shakes up retail ratings ahead of earnings with six changes
LMND Lemonade
$19.95 /

+0.16 (+0.81%)

GOEV Canoo
$2.23 /

-0.025 (-1.11%)

EVGO EVgo
$7.65 /

-0.45 (-5.56%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CTRN Citi Trends
$25.14 /

+1.16 (+4.84%)

CHWY Chewy
$38.24 /

+1.59 (+4.34%)

  • 22
    Apr
LMND Lemonade
$19.95 /

+0.16 (+0.81%)

GOEV Canoo
$2.23 /

-0.025 (-1.11%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CTRN Citi Trends
$25.14 /

+1.16 (+4.84%)

CHWY Chewy
$38.24 /

+1.59 (+4.34%)

LMND Lemonade
$19.95 /

+0.16 (+0.81%)

GOEV Canoo
$2.23 /

-0.025 (-1.11%)

EVGO EVgo
$7.65 /

-0.45 (-5.56%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CTRN Citi Trends
$25.14 /

+1.16 (+4.84%)

CHWY Chewy
$38.24 /

+1.59 (+4.34%)

LMND Lemonade
$19.95 /

+0.16 (+0.81%)

GOEV Canoo
$2.23 /

-0.025 (-1.11%)

EVGO EVgo
$7.65 /

-0.45 (-5.56%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

CHWY Chewy
$38.24 /

+1.59 (+4.34%)

Periodicals
Lennar, Nucor among home-building and steel stocks worth a look, Barron's says » 09:47
06/25/22
06/25
09:47
06/25/22
09:47
DHI

D.R. Horton

$67.69 /

+0.23 (+0.34%)

, LEN

Lennar

$71.94 /

+1.2 (+1.70%)

, TOL

Toll Brothers

$45.03 /

+0.555 (+1.25%)

, CLF

Cleveland-Cliffs

$16.49 /

+0.82 (+5.23%)

, NUE

Nucor

$111.05 /

+4.99 (+4.70%)

, STZHF

Stelco Holdings

$26.85 /

+1.1 (+4.27%)

, STLD

Steel Dynamics

$68.92 /

+2.9 (+4.39%)

, X

U.S. Steel

$19.85 /

+0.84 (+4.42%)

Two industries stand out…

Two industries stand out when looking for the cheapest stocks in the market now, namely home builders and steel makers, Andrew Bary writes in this week's edition of Barron's. Investors have dumped home-building and steel stocks on recession fears, but while a doubling in mortgage rates to 6% is reducing housing demand, a prolonged and deep downturn seems unlikely, given strong demographic trends and limited supply, the author notes. The publication highlights 8 stocks: D.R. Horton (DHI), Lennar (LEN), Toll Brothers (TOL), Cleveland-Cliffs (CLF), Nucor (NUE), Stelco Holdings (STZHF), Steel Dynamics (STLD) and U.S. Steel (X). Reference Link

ShowHide Related Items >><<
X U.S. Steel
$19.85 /

+0.84 (+4.42%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

06/21/22 Citi
D.R. Horton price target lowered to $73 from $89 at Citi
06/16/22 UBS
D.R. Horton price target lowered to $105 from $151 at UBS
06/08/22 Barclays
D.R. Horton price target lowered to $96 from $104 at Barclays
06/06/22 BTIG
D.R. Horton price target lowered to $97 from $104 at BTIG
LEN Lennar
$71.94 /

+1.2 (+1.70%)

06/22/22 UBS
Lennar price target lowered to $106 from $108 at UBS
06/22/22 KeyBanc
Lennar price target lowered to $60 from $75 at KeyBanc
06/22/22 BTIG
Lennar price target raised to $97 from $92 at BTIG
06/22/22 Wedbush
Lennar price target lowered to $88 from $130 at Wedbush
TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

06/21/22 Citi
Toll Brothers price target lowered to $44 from $49 at Citi
06/17/22 Wells Fargo
Toll Brothers downgraded to Equal Weight from Overweight at Wells Fargo
06/16/22 UBS
Toll Brothers price target lowered to $59 from $74 at UBS
05/31/22 Raymond James
Toll Brothers price target lowered to $75 from $82 at Raymond James
CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

06/14/22 JPMorgan
Cleveland-Cliffs price target lowered to $37 from $43 at JPMorgan
05/31/22 Goldman Sachs
Cleveland-Cliffs price target lowered to $27 from $36 at Goldman Sachs
04/25/22 B. Riley
Cleveland-Cliffs price target raised to $47 from $46 at B. Riley
04/19/22 Credit Suisse
Cleveland-Cliffs price target raised to $37 from $34 at Credit Suisse
NUE Nucor
$111.05 /

+4.99 (+4.70%)

06/14/22 JPMorgan
Nucor price target lowered to $125 from $146 at JPMorgan
05/31/22 Goldman Sachs
Nucor price target lowered to $130 from $148 at Goldman Sachs
05/17/22 BMO Capital
Nucor price target lowered to $128 from $168 at BMO Capital
04/25/22 Argus
Nucor price target raised to $190 from $140 at Argus
STZHF Stelco Holdings
$26.85 /

+1.1 (+4.27%)

06/02/22 Scotiabank
Stelco Holdings price target raised to C$57 from C$53 at Scotiabank
05/09/22 RBC Capital
Stelco Holdings price target raised to C$62 from C$61 at RBC Capital
05/09/22 Scotiabank
Stelco Holdings price target lowered to C$53 from C$56 at Scotiabank
04/14/22 RBC Capital
Stelco Holdings price target raised to C$61 from C$60 at RBC Capital
STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

06/14/22 JPMorgan
Steel Dynamics price target lowered to $110 from $129 at JPMorgan
05/31/22 Goldman Sachs
Steel Dynamics downgraded to Neutral from Buy at Goldman Sachs
04/22/22 BMO Capital
Steel Dynamics price target raised to $104 from $95 at BMO Capital
03/24/22 JPMorgan
Steel Dynamics price target raised to $117 from $95 at JPMorgan
X U.S. Steel
$19.85 /

+0.84 (+4.42%)

06/17/22 BMO Capital
U.S. Steel price target lowered to $23 from $30 at BMO Capital
06/17/22 Credit Suisse
U.S. Steel price target lowered to $44 from $49 at Credit Suisse
06/14/22 JPMorgan
U.S. Steel price target lowered to $28 from $34 at JPMorgan
05/31/22 Goldman Sachs
U.S. Steel price target lowered to $22 from $36 at Goldman Sachs
X U.S. Steel
$19.85 /

+0.84 (+4.42%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

X U.S. Steel
$19.85 /

+0.84 (+4.42%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

X U.S. Steel
$19.85 /

+0.84 (+4.42%)

TOL Toll Brothers
$45.03 /

+0.555 (+1.25%)

STLD Steel Dynamics
$68.92 /

+2.9 (+4.39%)

NUE Nucor
$111.05 /

+4.99 (+4.70%)

LEN Lennar
$71.94 /

+1.2 (+1.70%)

DHI D.R. Horton
$67.69 /

+0.23 (+0.34%)

CLF Cleveland-Cliffs
$16.49 /

+0.82 (+5.23%)

Periodicals
Carvana delivered undriveable cars, Barron's says » 09:40
06/25/22
06/25
09:40
06/25/22
09:40
CVNA

Carvana

$31.51 /

+2.73 (+9.49%)

, AMZN

Amazon.com

$116.68 /

+4.15 (+3.69%)

Carvana's (CVNA)…

Carvana's (CVNA) used cars often arrive at customers' homes with the same convenience as Amazon (AMZN)-delivered paper towels. But as the economy has reopened, Carvana's efforts to resume its torrid pandemic-era sales pace have been complicated by an inconvenient side effect of the growth: In its haste to seize market share from competitors, Carvana was selling cars faster than it could get them registered to their new owners, Jacob Adelman writes in this week's edition of Barron's. Carvana says many of the delays involved internal paperwork problems and slow work by third-party registration services and state motor vehicle agencies. In other instances, Carvana sold cars before it had title to the vehicles, an action that is illegal in many states where the company does business, the author notes. Reference Link

ShowHide Related Items >><<
CVNA Carvana
$31.51 /

+2.73 (+9.49%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

06/13/22 Stephens
Carvana price target lowered to $38 from $100 at Stephens
05/19/22 BofA
Carvana price target lowered to $80 from $225 at BofA
05/16/22 Needham
Carvana price target lowered to $80 from $121 at Needham
05/16/22 DA Davidson
Carvana price target lowered to $49 from $140 at DA Davidson
AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

06/24/22 Evercore ISI
Amazon price target lowered to $180 from $205 at Evercore ISI
06/16/22 Credit Suisse
Credit Suisse says Microsoft Azure growth opportunity not reflected in estimates
06/14/22 Morgan Stanley
AWS has 'small' risk from potential start-up spend slowdown, says Morgan Stanley
06/14/22 JPMorgan
Amazon remains best idea at JPMorgan with $200 price target
CVNA Carvana
$31.51 /

+2.73 (+9.49%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

  • 22
    Apr
CVNA Carvana
$31.51 /

+2.73 (+9.49%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

CVNA Carvana
$31.51 /

+2.73 (+9.49%)

AMZN Amazon.com
$116.68 /

+4.15 (+3.69%)

General news
Fed dove Daly thinks a 75 bp hike in July is likely needed » 22:20
06/24/22
06/24
22:20
06/24/22
22:20
$ECON

Economic Data

/

+

Fed dove Daly thinks a 75…

Fed dove Daly thinks a 75 bp hike in July is likely needed bas she wants to get to neutral as quickly as possible. But she does not want to overcorrect. A 50 bp increase could be warranted if the economy slows more than expected. She sees neutral closer to 3.1% and added it is around 2.5% when inflation is stable around 2%. Longer run inflation expectations are still fairly well anchored, she added. Daly is a non-voter.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Fed dove Daly thinks a 75 bp hike in July is likely needed » 22:10
06/24/22
06/24
22:10
06/24/22
22:10
$ECON

Economic Data

/

+

Fed dove Daly thinks a 75…

Fed dove Daly thinks a 75 bp hike in July is likely needed bas she wants to get to neutral as quickly as possible. But she does not want to overcorrect. A 50 bp increase could be warranted if the economy slows more than expected. She sees neutral closer to 3.1% and added it is around 2.5% when inflation is stable around 2%. Longer run inflation expectations are still fairly well anchored, she added. Daly is a non-voter.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Treasury Market Summary: » 21:50
06/24/22
06/24
21:50
06/24/22
21:50
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: risk appetite surged into the weekend with hefty gains across global equity markets. Fading recession fears, signs of slowing inflation, and reduced concerns over hawkish central banks helped fuel a strong relief rally in stocks. Much of the catalyst for today's actions was the slip in the inflation expectations gauges versus the the strength in the preliminary numbers. Fed hawk Bullard also played down recession risks. Wall Street climbed with the NASDAQ spiking 3.34%, while the S&P 500 increased 3.06% and the Dow jumped 2.68%. Bonds sold off, though the rise in rates was modest in comparison to the jump in stocks. The belly generally underperformed amid added weight from upcoming bond auctions. Yields drifted higher into the close as buying petered out. The wi 2-year yield cheapened 1.5 bps to 3.055%, with the wi 5-year up 2.5 bps to 3.180% and the 7-year up 3 bps to 3.190%. The 10-year was 3.4 bps higher at 3.121%. The curve vacillated narrowly around 6 bps. The dollar index lost some ground and fell to 104.121 from a high of 104.513 as haven demand and rate hike expectations softened. On the other hand WTI oil prices firmed above $108 before dipping and closing at $107.62. Gold extended modestly higher to $1826.88.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Hot Stocks
Raytheon Technologies unit chosen by MDA to develop counter-hypersonic missile » 18:38
06/24/22
06/24
18:38
06/24/22
18:38
RTX

Raytheon Technologies

$94.15 /

+2.4 (+2.62%)

The Missile Defense…

The Missile Defense Agency has selected Raytheon Missiles & Defense, a Raytheon Technologies business, to continue to develop a first-of-its-kind counter-hypersonic missile, the Glide Phase Interceptor. GPI is designed to intercept hypersonic weapons in the glide phase of flight, providing the U.S. and allies with an additional layer of defense against regional hypersonic missile threats. This firm fixed price Other Transaction Agreement modification, valued at $41M, increases the total value to $62M and allows Raytheon Missiles & Defense to continue maturing its GPI design using advanced materials and technology required to intercept a hypersonic threat. This phase will also finalize systems requirements and support accelerated development timelines.

ShowHide Related Items >><<
RTX Raytheon Technologies
$94.15 /

+2.4 (+2.62%)

RTX Raytheon Technologies
$94.15 /

+2.4 (+2.62%)

04/27/22 Argus
Raytheon Technologies price target raised to $112 from $100 at Argus
04/27/22 Cowen
Raytheon Technologies price target raised to $120 from $115 at Cowen
04/08/22 RBC Capital
Raytheon Technologies initiated with an Outperform at RBC Capital
03/29/22 Jefferies
Northrop among biggest beneficiaries of DoD budget request, says Jefferies
RTX Raytheon Technologies
$94.15 /

+2.4 (+2.62%)

RTX Raytheon Technologies
$94.15 /

+2.4 (+2.62%)

RTX Raytheon Technologies
$94.15 /

+2.4 (+2.62%)

RTX Raytheon Technologies
$94.15 /

+2.4 (+2.62%)

Hot Stocks
Antelope Enterprise Holdings receives Nasdaq deficiency letter » 18:26
06/24/22
06/24
18:26
06/24/22
18:26
AEHL

Antelope Enterprise Holdings

$1.04 /

+ (+0.00%)

Antelope Enterprise…

Antelope Enterprise Holdings announced its receipt of a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market. The company received the deficiency letter on June 23, which notified the company that for the last 30 consecutive business days the bid price for the company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The deficiency letter does not result in the immediate delisting of the company's common stock from the Nasdaq Capital Market.

Hot Stocks
Embraer signs firm order for 10 E-Jets P2F conversions » 18:03
06/24/22
06/24
18:03
06/24/22
18:03
ERJ

Embraer

$9.50 /

+0.185 (+1.99%)

Embraer has signed a firm…

Embraer has signed a firm order for up to 10 Embraer E-Jets Passenger to Freight conversions with an undisclosed customer. Aircraft for conversion will come from the customer's current E-Jets fleet, with deliveries starting in 2024. This is the first firm contract for Embraer's P2F, being the second agreement for this kind of operation. In May, Embraer and Nordic Aviation Capital announced an agreement in principle to take up to 10 conversion slots for E190F/E195F. Embraer's E-Jets P2F conversions deliver segment-leading performance and economics. The E-Jets Freighters will have over 50% more volume capacity, three times the range of large cargo turboprops, and up to 30% lower operating costs than narrow bodies.

ShowHide Related Items >><<
ERJ Embraer
$9.50 /

+0.185 (+1.99%)

ERJ Embraer
$9.50 /

+0.185 (+1.99%)

05/09/22 Citi
Citi places 'positive, 30-day Catalyst Watch' on Embraer shares
04/26/22 Citi
Embraer price target lowered to $13 from $14.50 at Citi
01/20/22 Morgan Stanley
Embraer upgraded to Overweight from Equal Weight at Morgan Stanley
12/23/21
Fly Intel: Top five analyst upgrades
ERJ Embraer
$9.50 /

+0.185 (+1.99%)

ERJ Embraer
$9.50 /

+0.185 (+1.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.